Title: Efficacy and Safety of Olutasidenib Monotherapy in Primary Refractory AML: A Post Hoc Analysis of a Phase 2 Study Presenter: Antonio Curti, M.D., Ph.D. In the pivotal cohort of R/R AML patients ...
SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback